US Stock MarketDetailed Quotes
MRNS Marinus Pharmaceuticals
- 1.430
- +0.040+2.88%
Close Jul 19 16:00 ET
- 1.439
- +0.009+0.64%
Post 19:38 ET
78.56MMarket Cap-541P/E (TTM)
1.445High1.365Low627.83KVolume1.380Open1.390Pre Close881.77KTurnover1.67%Turnover RatioLossP/E (Static)54.93MShares11.26052wk High-4.78P/B53.93MFloat Cap1.10052wk Low--Dividend TTM37.71MShs Float82.880Historical High--Div YieldTTM5.76%Amplitude1.100Historical Low1.404Avg Price1Lot Size
Marinus Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 9.68%-37.46M | -4.53%-118M | -23.17%-26.99M | 15.09%-25.17M | 27.66%-24.36M | -49.98%-41.48M | -103.48%-112.89M | -0.75%-21.91M | -648.68%-29.65M | -46.69%-33.67M |
| Net income from continuing operations | -11.34%-38.67M | -613.59%-141.41M | -21.73%-41.77M | -144.99%-32.97M | 19.02%-31.93M | -79.38%-34.73M | 79.94%-19.82M | -21.22%-34.31M | 475.71%73.29M | -65.52%-39.43M |
| Operating gains losses | ---- | ---- | ---- | ---- | ---- | ---- | -11,345.70%-106.45M | --0 | ---107.38M | --0 |
| Depreciation and amortization | -16.56%131K | 31.82%551K | 52.44%125K | -10.13%142K | 36.56%127K | 84.71%157K | 17.75%418K | -11.83%82K | 73.63%158K | 8.14%93K |
| Other non cash items | -2.90%1.61M | 51.91%5.06M | -113.08%-207K | 1,141.67%1.79M | 381.00%1.82M | 35.18%1.66M | 212.77%3.33M | 397.80%1.58M | -55.28%144K | 40.37%379K |
| Change In working capital | 54.06%-5.58M | 135.60%2.17M | 58.39%9.94M | 1,522.22%2.19M | 47.93%2.18M | 13.15%-12.14M | -121.23%-6.09M | 63.80%6.28M | -99.38%135K | 159.34%1.47M |
| -Change in prepaid assets | 57.24%-3.83M | 54.24%-2.55M | 214.52%3.74M | 585.12%1.15M | 208.02%1.52M | -736.10%-8.96M | -553.81%-5.58M | -716.00%-3.26M | -70.21%168K | -1.88%-1.41M |
| -Change in payables and accrued expense | 39.09%-2.26M | -43.85%2.11M | 109.73%5.67M | 200.95%529K | -115.73%-371K | -374.71%-3.72M | -52.12%3.75M | -18.86%2.7M | -285.82%-524K | 315.24%2.36M |
| -Change in other current liabilities | ---- | --0 | --0 | --0 | ---- | ---- | -200.00%-22.16M | --0 | --0 | --0 |
| -Change in other working capital | -4.04%522K | -85.40%2.61M | -92.19%534K | 3.87%510K | 96.74%1.03M | -94.58%544K | 4,058.85%17.89M | 1,107.95%6.84M | --491K | --521K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 9.68%-37.46M | -4.53%-118M | -23.17%-26.99M | 15.09%-25.17M | 27.66%-24.36M | -49.98%-41.48M | -103.48%-112.89M | -0.75%-21.91M | -648.68%-29.65M | -46.69%-33.67M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 140.17%20.89M | -127.04%-28.61M | 8,084.81%6.47M | -88.77%11.92M | 1,593.73%5M | -60,359.30%-52M | 7,575.05%105.77M | 110.96%79K | 12,269.04%106.11M | 61.23%-335K |
| Net PPE purchase and sale | ---- | 93.14%-110K | -143.04%-34K | 93.66%-80K | ---- | ---- | 44.51%-1.6M | 110.96%79K | -44.61%-1.26M | 61.23%-335K |
| Net investment purchase and sale | 140.17%20.89M | -126.54%-28.5M | --6.5M | -88.82%12M | --5M | ---52M | 7,184.60%107.38M | --0 | --107.38M | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 140.17%20.89M | -127.04%-28.61M | 8,084.81%6.47M | -88.77%11.92M | 1,593.73%5M | -60,359.30%-52M | 7,575.05%105.77M | 110.96%79K | 12,269.04%106.11M | 61.23%-335K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 247.70%257K | -78.65%26.63M | -99.30%661K | 4,844.14%25.9M | 1,592.86%237K | -100.56%-174K | 201.96%124.74M | 31,595.96%94.14M | -101.94%-546K | -99.89%14K |
| Net issuance payments of debt | --0 | --0 | -97.52%737K | 43.77%-316K | ---247K | -100.59%-174K | 45.33%58.51M | --29.67M | -102.01%-562K | --0 |
| Net common stock issuance | ---- | -59.95%25.82M | -100.15%-97K | ---- | ---- | ---- | --64.48M | --64.48M | ---- | ---- |
| Proceeds from stock option exercised by employees | --257K | -55.18%804K | -32.26%21K | 1,768.75%299K | 3,357.14%484K | --0 | 49.62%1.79M | -89.56%31K | -84.16%16K | -97.49%14K |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | ---- | 71.62%-42K | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 247.70%257K | -78.65%26.63M | -99.30%661K | 4,844.14%25.9M | 1,592.86%237K | -100.56%-174K | 201.96%124.74M | 31,595.96%94.14M | -101.94%-546K | -99.89%14K |
| Net cash flow | ||||||||||
| Beginning cash position | -49.88%120.57M | 95.69%240.55M | -16.53%140.44M | 38.41%127.79M | 16.30%146.9M | 95.69%240.55M | -11.25%122.93M | 15.95%168.25M | -17.93%92.33M | 2.31%126.32M |
| Current changes in cash | 82.57%-16.32M | -202.00%-119.98M | -127.48%-19.87M | -83.34%12.65M | 43.76%-19.12M | -2,860.82%-93.65M | 854.87%117.62M | 426.07%72.3M | 132.84%75.92M | -209.62%-33.99M |
| End cash Position | -29.03%104.25M | -49.88%120.57M | -49.88%120.57M | -16.53%140.44M | 38.41%127.79M | 16.30%146.9M | 95.69%240.55M | 95.69%240.55M | 15.95%168.25M | -17.93%92.33M |
| Free cash flow | 9.68%-37.46M | -3.02%-118.12M | -22.81%-27.03M | 18.27%-25.26M | 28.37%-24.36M | -49.52%-41.48M | -96.45%-114.66M | 2.07%-22.01M | -782.10%-30.91M | -42.77%-34.01M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg